Su N - Search Results

1

Systemic chemotherapy and sequential locoregional radiotherapy in initially metastatic nasopharyngeal carcinoma: Retrospective analysis with 821 cases.

Huang T, Su N, Zhang X, Ma S, Zhong G, Tian X, Chen Q, Tang L, Lu L, Fang Y, Cai J, Cai Q. Huang T, et al. Among authors: su n. Head Neck. 2020 Aug;42(8):1970-1980. doi: 10.1002/hed.26130. Epub 2020 Mar 10. Head Neck. 2020. PMID: 32154638

2

A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma.

Tian XP, Su N, Wang L, Huang WJ, Liu YH, Zhang X, Huang HQ, Lin TY, Ma SY, Rao HL, Li M, Liu F, Zhang F, Zhong LY, Liang L, Lan XL, Li J, Liao B, Li ZH, Tang QL, Liang Q, Shao CK, Zhai QL, Cheng RF, Sun Q, Ru K, Gu X, Lin XN, Yi K, Shuang YR, Chen XD, Dong W, Sun C, Sang W, Liu H, Zhu ZG, Rao J, Guo QN, Zhou Y, Meng XL, Zhu Y, Hu CL, Jiang YR, Zhang Y, Gao HY, He WJ, Xia ZJ, Pan XY, Hai L, Li GW, Song LY, Kang TB, Xie D, Cai QQ. Tian XP, et al. Among authors: su n. Clin Cancer Res. 2020 Jul 15;26(14):3760-3770. doi: 10.1158/1078-0432.CCR-19-4207. Epub 2020 Mar 31. Clin Cancer Res. 2020. PMID: 32234760

3

A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma.

Tian XP, Ma SY, Young KH, Ong CK, Liu YH, Li ZH, Zhai QL, Huang HQ, Lin TY, Li ZM, Xia ZJ, Zhong LY, Rao HL, Li M, Cai J, Zhang YC, Zhang F, Su N, Li PF, Zhu F, Xu-Monette ZY, Wong EKY, Ha JCH, Khoo LP, Ai L, Cheng RF, Lim JQ, de Mel S, Ng SB, Lim ST, Cai QQ. Tian XP, et al. Among authors: su n. Blood. 2021 Aug 12;138(6):452-463. doi: 10.1182/blood.2020010637. Blood. 2021. PMID: 33728448 Free article. Clinical Trial.

4

A prognostic immune risk score for diffuse large B-cell lymphoma.

Ma SY, Tian XP, Cai J, Su N, Fang Y, Zhang YC, Wang JN, Peter Gale R, Cai QQ. Ma SY, et al. Among authors: su n. Br J Haematol. 2021 Jul;194(1):111-119. doi: 10.1111/bjh.17478. Epub 2021 May 3. Br J Haematol. 2021. PMID: 33942291

5

A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study.

Cai J, Tian X, Ma S, Zhong L, Li W, Wang L, Guo L, Li Z, Wu Y, Zhong G, Huang H, Xia Z, Xia Y, Liu P, Su N, Fang Y, Zhang Y, Cai Q. Cai J, et al. Among authors: su n. Br J Cancer. 2021 Aug;125(3):402-412. doi: 10.1038/s41416-021-01434-6. Epub 2021 May 19. Br J Cancer. 2021. PMID: 34012033 Free PMC article.

6

Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.

Wang J, Fang Y, Ma S, Su N, Zhang Y, Huang H, Li Z, Huang H, Tian X, Cai J, Xia Y, Liu P, Cai Q. Wang J, et al. Among authors: su n. Leuk Res. 2021 Dec;111:106705. doi: 10.1016/j.leukres.2021.106705. Epub 2021 Sep 14. Leuk Res. 2021. PMID: 34534908

7

Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.

Zhang YC, Wang JN, Ma SY, Cai J, Su N, Huang HQ, Li ZM, Xia ZJ, Huang H, Liu PP, Xia Y, Cai QQ. Zhang YC, et al. Among authors: su n. Br J Haematol. 2022 Jan;196(1):127-135. doi: 10.1111/bjh.17849. Epub 2021 Oct 7. Br J Haematol. 2022. PMID: 34618912

8

Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.

Fang Y, Su N, Ma S, Cai J, Zhong L, Li W, Huang H, Li Z, Huang H, Xia Y, Liu P, Guo L, Li Z, Wu Y, Tian X, Wang J, Zhang Y, Cai Q. Fang Y, et al. Among authors: su n. Ann Hematol. 2022 Mar;101(3):595-605. doi: 10.1007/s00277-021-04739-x. Epub 2022 Jan 5. Ann Hematol. 2022. PMID: 34985557

9

Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.

Wang J, Su N, Fang Y, Ma S, Zhang Y, Cai J, Zou Q, Tian X, Xia Y, Liu P, Li Z, Huang H, Huang H, Cai Q. Wang J, et al. Among authors: su n. Front Immunol. 2022 Feb 2;13:835103. doi: 10.3389/fimmu.2022.835103. eCollection 2022. Front Immunol. 2022. PMID: 35185926 Free PMC article.

10

The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study.

Li L, Zhang H, Xie Y, Su N, Su S, Zhang X, Cen W. Li L, et al. Among authors: su s, su n. Comput Math Methods Med. 2022 Feb 25;2022:1475871. doi: 10.1155/2022/1475871. eCollection 2022. Comput Math Methods Med. 2022. Retraction in: Comput Math Methods Med. 2023 Nov 1;2023:9789208. doi: 10.1155/2023/9789208 PMID: 35251294 Free PMC article. Retracted. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,411 results

Search Page

Filters